Cardiol Therapeutics Inc.

Why expand a Phase III trial after observing fewer disease recurrences than expected? Our President/CEO David Elsley joins Lyndsay Malchuk on Market Frontlines to discuss the rationale behind Cardiol’s expanded MAVERIC trial, the blinded data and what comes next for CardiolRx™. $CRDL Watch the full interview ⬇️ youtube.com/watch?v=hFjOZinz…

Our President & CEO David Elsley joined @smallcapsteve on @TheDeepDive_ca last week to discuss the latest progress with Phase III MAVERIC, and the bigger picture for inflammation in cardiovascular disease. The conversation covers the decision to expand MAVERIC, the path toward a potential NDA, recent developments across the cardiac inflammation landscape and what Cardiol is working toward in 2027. $CRDL Watch the full interview ⬇️ youtube.com/watch?v=dRZigF7H…

Phase III MAVERIC reached its 110-patient enrollment target ahead of schedule, and @CardiolRx is expanding the trial to up to 150 patients to preserve its planned statistical power and further strengthen the trial. Our President & CEO David Elsley dives deeper into the decision on @EllisMartinRprt. $CRDL youtube.com/watch?v=RT7J2g1u…

For 20 to 30% of people with pericarditis, the condition returns within 18 months of a first episode. They know the signs well: severe chest pain, breathlessness and fatigue that come back after the condition seemed to resolve, often with another hospital visit. What they need are more accessible, safer and better tolerated oral treatment options that address the inflammation behind each recurrence. MAVERIC, @CardiolRx pivotal phase III trial evaluating CardiolRx™ for reducing the risk of pericarditis recurrence, is expanding to up to 150 patients. Topline data are expected in mid-2027. #MAVERIC $CRDL cardiolrx.com/the-signs-that…

Our leading clinical program in recurrent pericarditis, the ongoing pivotal MAVERIC Phase III trial, is designed to evaluate whether CardiolRx™ can reduce the risk of pericarditis recurrence. The study is enrolling up to 150 patients across up to 25 clinical sites, including the Mayo Clinic, Cleveland Clinic, Northwestern University and more. ✅ +20 clinical sites recruiting ✅ Topline results anticipated mid-2027 ✅ Existing capital expected to fund MAVERIC completion #MAVERIC #CardiolRx $CRDL

Cardiol has reached its 110-patient target in the pivotal Phase III MAVERIC trial of CardiolRx™, ahead of guidance. A blinded review showed fewer recurrences than anticipated, and with that encouraging development we are now expanding enrollment to up to 150 to ensure sufficient events for a robust assessment of CardiolRx™’s potential to reduce recurrence risk. We anticipate MAVERIC topline data in mid-2027 following the expansion of the trial. $CRDL cardiolrx.com/cardiol-therap…

For many people with recurrent pericarditis, the hardest part often comes before any treatment. Years of severe chest pain and repeated emergency visits, often with tests that come back normal and no clear answer. Emily's story is one that thousands of patients will recognize, and understanding the disease is where better care begins. MAVERIC is positioned as a defining catalyst that could significantly shape @CardiolRx’s future trajectory. #RecurrentPericarditis #MAVERIC $CRDL

We're pleased to announce the Company has received proceeds of over USD $7M from the exercise of outstanding common share purchase warrants. Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. #Biotech #LifeSciences $CRDL cardiolrx.com/cardiol-therap…

REMINDER: Cardiol Therapeutics management will participate in a Fireside Chat at the @HCWCO 28th Annual Global Investment Conference TODAY at 10:30 a.m. EDT. 📅 Monday, September 14 at 10:30 a.m. EDT 📺 Click the link below to watch live journey.ct.events/view/64753… #Biotech #LifeSciences #Cardiol #FiresideChat $CRDL

We're pleased to share that Cardiol Therapeutics will participate in a Fireside Chat at @HCWCO 28th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT. 📅 Monday, September 14 at 10:30 a.m. EDT 📍 Lotte New York Palace Hotel, Louis (4th Floor) 💻 Register to watch live on Cardiolrx.com #Biotech #LifeSciences #HeartHealth $CRDL cardiolrx.com/cardiol-therap…

About 40,000 people in the United States live with recurrent pericarditis. For the most stubborn cases, the therapies available today can help, but they often mean ongoing injections and a treatment that suppresses the immune system. Understanding those trade-offs is part of building something better for patients. #RecurrentPericarditis #CardiovascularDisease $CRDL

Recurrent Pericarditis affects an estimated 40,000 people in the U.S., yet few outside the medical community have heard its name. Find out what happens inside the heart when the pericardium becomes inflamed, and why, for many patients, the disease keeps returning despite the treatments available today. #RecurrentPericarditis #InflammatoryHeartDisease $CRDL

The @CardiolRx team is on the ground at #ESCCongress 2026 in Munich, Germany, connecting with the global cardiology community advancing science in inflammatory heart disease. Excited to engage with peers, clinicians & researchers shaping the future of cardiovascular care. $CRDL #ESC2026 #Cardiology #HeartDisease

Congratulations to Dr. Massimo Imazio, Co-chair of our Phase III MAVERIC Program and @PericarditisA Board Member, on the publication of his new book! 📖 Dr. Imazio's clinical expertise is helping guide MAVERIC, our pivotal Phase III trial evaluating CardiolRx™ for recurrent pericarditis. This new guide reflects the same commitment to improving quality of life for patients living with this disease.

CardiolRx™ is supported by a strong scientific rationale targeting inflammatory and pro-fibrotic pathways central to multiple forms of heart disease. Importantly, this same biological foundation extends beyond recurrent pericarditis into additional indications, including acute myocarditis, and heart failure with CRD-38. Together, these programs position @CardiolRx as more than a single-asset company, establishing a broader platform targeting inflammatory heart disease.

CardiolRx™ is designed to offer a differentiated approach to treating recurrent pericarditis. Phase II MAVERIC data demonstrated: ✅ Rapid and sustained reductions in pericarditis pain ✅ Meaningful reductions in inflammation ✅ Fewer recurrence episodes ✅ Favorable safety and tolerability This profile compares advantageously to injectable biologics, which are associated with immunosuppression, injection burden, treatment dependency, and recurrence risk following discontinuation. CardiolRx™ aims to address these limitations while delivering clinically meaningful outcomes for patients including the reduction in the risk of pericarditis recurrence. $CRDL

The pivotal Phase III MAVERIC program is guided by a globally recognized group of experts in pericarditis and cardiovascular inflammation. Notably, members of this leadership team were involved in the design of another pivotal recurrent pericarditis trial, which led to the FDA approval of rilonacept. This depth of clinical expertise strengthens both the scientific foundation and execution quality of MAVERIC. $CRDL